Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 8.01, 9.01 · 8-K

Biofrontera Inc.

BFRINASDAQEQUITYCurrent

Other Events

Item 8.01 Other Events. On September 14, 2026, Biofrontera Inc. (the “Company”) issued a press release announcing that it has received notification from the U.S. Food and Drug Administration (the “FDA”) that the FDA had approved the Company’s supplemental New Drug Application for Ameluz ® (aminolevulinic acid hydrochloride) topical gel, 10%, in combination with photodynamic therapy using the BF-Rh…

Filed Sep 14, 2026Accepted Sep 14, 2026, 9:29 AM EDTCIK 1858685Accession 0001493152-26-042508
Share

Company context

Current securities

Historical securities (1)

Recent company filings

  1. 10-Q filingNov 13, 2026
  2. SCHEDULE 13G/A - filed by Rosalind Advisors, Inc. regarding Biofrontera Inc.Nov 13, 2026
  3. Results of Operations and Financial ConditionNov 13, 2026
  4. 25-NSE - filed by Nasdaq Stock Market LLC regarding Biofrontera Inc.Oct 30, 2026
  5. 10-Q filingAug 13, 2026

Registered securities in this filing

Biofrontera Inc. · 8-K · Filed 2026-09-14

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common stock, par value $0.001 per share

Symbol
BFRI
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: From2026-09-142026-09-14_custom_CommonStockParValue0.001PerShareMember

Dimensions: us-gaap:StatementClassOfStockAxis

Warrants to purchase common stock

Symbol
BFRIW
Exchange
NASDAQ
Classification
WARRANT
Status
Historical · closed Nov 2, 2026
Filing context

Context: From2026-09-142026-09-14_custom_WarrantsToPurchaseCommonStockMember

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000149315226042508 · 2 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events. On September 14, 2026, Biofrontera Inc. (the “Company”) issued a press release announcing that it has received notification from the U.S. Food and Drug Administration (the “FDA”) that the FDA had approved the Company’s supplemental New Drug Application for Ameluz ® (aminolevulinic acid hydrochloride) topical gel, 10%, in combination with photodynamic therapy using the BF-RhodoLED ® lamp series, for the treatment of superficial basal cell carcinoma in adults. A copy of the press release is being furnished as Exhibit 99.1 attached to this Current Report on Form 8-K. The information contained in Item 8.01 of this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing by the company under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 (by filename) ex99-1.htm

EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma Ameluz used in conjunction with the RhodoLED lamp becomes the first and only photodynamic therapy approved in the United States to treat a skin cancer, creating an additional growth opportunity for Biofrontera’s photodynamic therapy platform WOBURN, Mass., September 14, 2026 - Biofrontera Inc. (NASDAQ: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s supplemental New Drug Application (sNDA) for Ameluz ® (aminolevulinic acid hydrochloride) topical gel, 10%, in combination with photodynamic therapy using the BF-RhodoLED ® lamp series, for the treatment of superficial Basal Cell Carcinoma (sBCC) in adults 1. With this approval, Ameluz becomes the first and only PDT drug approved by the FDA for the treatment of a skin cancer, and the only topical PDT in the United States indicated to treat both a pre-cancerous skin co…

Open exhibit ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.